Halozyme Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Halozyme Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than almost all Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $38 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 90% of Healthcare companies in United States.
- Self-Funding Ratio: Over the last 3 years its own operating cash covered its investment spending (capex) 4.7 times. Higher than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$146Over the last 3 years, every $100 of reported profit came with $146 of operating cash.
Lower than 53% of Healthcare companies in United States.
Self-Funding Ratio
4.7×Over the last 3 years its own operating cash covered its investment spending (capex) 4.7 times.
Higher than 86% of Healthcare companies in United States.
Cash Locked Ratio
$43For every $100 of sales, $43 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $47 tied up three years earlier.
More money tied up than 85% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$16Sales grew 112% in 3 years; of every extra $100 of sales, $16 became extra profit.
Lower than 54% of Healthcare companies in United States.
Asset Productivity Ratio
+112% / +37%In 3 years sales changed by +112% while total assets changed by +37%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
−14%Debt, after subtracting cash, equals 14% of its market value (net debt).
Lower than 81% of Healthcare companies in United States.
Tangible Assets Ratio
38%Of every $100 the company owns, $38 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 90% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than almost all Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Halozyme Therapeutics, Inc. owes $0.94 for every $1 it owns. Net profit fell 29% in the year to Dec 2025, and grew 16% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
36.4Investors pay $36.4 for every $1 of Halozyme Therapeutics, Inc.'s yearly profit, higher than 67% of Healthcare companies in United States.
P/B ratio
98.47The share price is 98.47 times Halozyme Therapeutics, Inc.'s book value per share, higher than almost all Healthcare companies in United States.
Market cap
$14.1 BThe total market value of all of Halozyme Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 93% of Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$144 MWhat Halozyme Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.26Net worth divided by the number of shares. The share price of $124.54 is 98.5 times this, which is the P/B above.
Return on equity (ROE)
173.7%Halozyme Therapeutics, Inc. earned 173.7% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
Owes vs Owns
0.94×Halozyme Therapeutics, Inc. owes $0.94 for every $1 it owns (high), higher than 85% of Healthcare companies in United States.
Dividend yield
NoneHalozyme Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+38%Revenue rose 38% in the year to Dec 2025, and grew 28% a year on average over 3 years.
Profit growth
-29%Net profit fell 29% in the year to Dec 2025, and grew 16% a year on average over 3 years.
Profit margin
22.7%Halozyme Therapeutics, Inc. keeps $23 of every $100 of revenue as net profit.
Cash quality
2.1×Cash from Halozyme Therapeutics, Inc.'s business was 2.1× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
44.3×Halozyme Therapeutics, Inc.'s operating profit covered its interest costs 44.3 times in the year to Dec 2025.
Cash vs debt
Net debtHalozyme Therapeutics, Inc. had $2.0 B more debt than cash (net debt) at Dec 2025.
Questions
What is Halozyme Therapeutics, Inc.'s P/E ratio?
Investors pay $36.4 for every $1 of Halozyme Therapeutics, Inc.'s yearly profit, higher than 67% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Halozyme Therapeutics, Inc.: $14.1 B ÷ $144 M (30 Jun 2026) = 98.5.
What is Halozyme Therapeutics, Inc.'s return on equity?
Halozyme Therapeutics, Inc. earned 173.7% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
How much does Halozyme Therapeutics, Inc. owe compared with what it owns?
Halozyme Therapeutics, Inc. owes $0.94 for every $1 it owns (high), higher than 85% of Healthcare companies in United States.
Does Halozyme Therapeutics, Inc. pay a dividend?
No. Halozyme Therapeutics, Inc. does not currently pay a dividend.
Is Halozyme Therapeutics, Inc.'s revenue growing?
Revenue rose 38% in the year to Dec 2025, and grew 28% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.